Overview

Safety and Pharmacokinetics of ODM-204 in Patients With Metastatic Castration-Resistant Prostate Cancer

Status:
Completed
Trial end date:
2019-01-01
Target enrollment:
Participant gender:
Summary
The purpose of this first-in-man study is to evaluate safety, tolerability and pharmacokinetics of ODM-204 in patients with metastatic castration-resistant prostate cancer.
Phase:
Phase 1/Phase 2
Details
Lead Sponsor:
Orion Corporation, Orion Pharma
Treatments:
Prednisone